Astra Zeneca

Astra Zeneca's reported carbon emissions

AstraZeneca, headquartered in the UK, has reported a total of approximately 6.88 billion kilograms of CO2e emissions for the year 2025. This figure encompasses Scope 1, 2, and 3 emissions. Specifically, Scope 1 emissions were around 62.59 million kg CO2e, Scope 2 (market-based) emissions were approximately 11.32 million kg CO2e, and Scope 3 emissions totalled roughly 6.20 billion kg CO2e. For the year 2024, total emissions were approximately 5.87 billion kg CO2e, with Scope 1 at about 125.39 million kg CO2e, Scope 2 (market-based) at approximately 14.21 million kg CO2e, and Scope 3 at approximately 5.72 billion kg CO2e. In 2023, total emissions were around 5.77 billion kg CO2e, with Scope 1 at approximately 180.90 million kg CO2e, Scope 2 (market-based) at around 19.94 million kg CO2e, and Scope 3 at approximately 5.59 billion kg CO2e. AstraZeneca is committed to significant emissions reductions. The company aims for a 98% absolute reduction in Scope 1 and 2 greenhouse gas (GHG) emissions by 2026, using a 2015 baseline. Furthermore, AstraZeneca has set targets to reduce absolute Scope 3 GHG emissions by 50% by 2030 and by 90% by 2045, both from a 2019 baseline. The company also aims for net-zero GHG emissions across its value chain by 2045. In line with these commitments, AstraZeneca is working towards a 100% renewable electricity consumption globally by 2025 and plans for its entire road fleet to be electric by the same year.